Moderna, Inc.
Every calculator, already run for MRNA
Open the full toolkit →You have the numbers on MRNA. Get the argument.
A written report on which of these readings actually decide the outcome for Moderna, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
23 analysts covering MRNAAnalyst Price Target Disagreement for Moderna, Inc.
Wall Street's bull case implies +16% from the current price; the bear case implies -69%. A 85% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for MRNA
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Moderna, Inc.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, i…
MRNA — frequently asked
Is MRNA a buy right now?
Wall Street's consensus rating on Moderna, Inc. is Hold across 23 analysts, with a mean price target of $119.56 (-18% vs. the current $146.48). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is MRNA overvalued?
MRNA trades at — trailing earnings, against a DCF fair value of $14 per share. The current price implies 39% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is MRNA's next earnings date?
Moderna, Inc. is next scheduled to report earnings around Nov 5, 2026. A full MRNA research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Moderna, Inc.?
Analysts covering Moderna, Inc. (MRNA) range from a bear-case target of $45.00 to a bull-case high of $170.00, with a mean consensus target of $119.56 across 18 analysts. The spread of $125.00 (85% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Moderna, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Moderna, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full MRNA research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Moderna, Inc., in minutes. 3 free reports included with every account — no credit card required.